Business Context and Reporting Period
This Form 6-K filing by Chemomab Therapeutics Ltd. covers the month of June 2026, specifically dated June 2, 2026. The report details significant changes to the composition of the Company's Board of Directors and its committees.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance updates and contains no financial performance data.
Material Changes
The following material changes to the Board of Directors and committees were effective immediately on the dates specified:
- Board Appointments: Gwen Melincoff was appointed as a Class I Director and Chair of the Nominating and Governance Committee on June 1, 2026. She is considered an independent director.
- Resignations: Claude Nicaise and Jill Quigley resigned from the Board and the Audit Committee on May 29, 2026. The filing states these resignations were not due to any disagreement with the Company.
- Audit Committee Changes: Neil Cohen and Dr. Nissim Darvish were appointed to the Audit Committee on June 1, 2026. The committee now consists of Neil Cohen (Chair), Dr. Nissim Darvish, and Dr. Alan Moses.
- Nominating Committee Changes: Neil Cohen resigned as Chair of the Nominating Committee on June 1, 2026. The committee now consists of Gwen Melincoff (Chair) and Dr. Nissim Darvish.
- Board Size: The Board size is now five directors.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, management commentary on business strategy, or specific risk factors. The only contingency noted is the confirmation that the resignations of Mr. Nicaise and Ms. Quigley were not the result of disagreements regarding operations, policies, or practices.
Key Facts for Investor Verification
- Verify the independence status and potential conflicts of interest for the newly appointed director, Gwen Melincoff.
- Confirm the effective dates of the resignations (May 29, 2026) and new appointments (June 1, 2026) for regulatory compliance.
- Review the biographical background of Ms. Melincoff to assess her specific expertise in biotechnology business development relative to Chemomab's pipeline.
- Check subsequent filings for any financial updates, as this 6-K contains no financial data.